Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Alpine Immune Sciences — Marketable securities by Quarter
Alpine Immune Sciences — Marketable securities ($M) ($M)
Vertex Pharmaceuticals Alpine Immune Sciences — Marketable securities: $273M in Q1 2024, up 51.1% from a year earlier. No newer figure appears in the documents we track.
Where the Q1 2024 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001626199 Alpine Immune Sciences).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Alpine Immune Sciences — Marketable securities ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q1 2024 | Mar 31, 2024 | 273 | +51.1% | SEC Filing ↗ |
| Q4 2023 | Dec 31, 2023 | 283 | +26.4% | SEC Filing ↗ |
| Q3 2023 | Sep 30, 2023 | 174 | +42.7% | SEC Filing ↗ |
| Q2 2023 | Jun 30, 2023 | 170 | +18.3% | SEC Filing ↗ |
| Q1 2023 | Mar 31, 2023 | 180 | +31.7% | SEC Filing ↗ |
| Q4 2022 | Dec 31, 2022 | 224 | +137.6% | SEC Filing ↗ |
| Q3 2022 | Sep 30, 2022 | 122 | +16.9% | SEC Filing ↗ |
| Q2 2022 | Jun 30, 2022 | 144 | +98.6% | SEC Filing ↗ |
| Q1 2022 | Mar 31, 2022 | 137 | +62.7% | SEC Filing ↗ |
| Q4 2021 | Dec 31, 2021 | 94.4 | +33.7% | SEC Filing ↗ |
| Q3 2021 | Sep 30, 2021 | 105 | – | SEC Filing ↗ |
| Q2 2021 | Jun 30, 2021 | 72.3 | +3,512.5% | SEC Filing ↗ |
| Q1 2021 | Mar 31, 2021 | 84.2 | +649.0% | SEC Filing ↗ |
| Q4 2020 | Dec 31, 2020 | 70.6 | +189.4% | SEC Filing ↗ |
| Q3 2020 | Sep 30, 2020 | 0 | -100.0% | SEC Filing ↗ |
| Q2 2020 | Jun 30, 2020 | 2 | -95.0% | SEC Filing ↗ |
| Q1 2020 | Mar 31, 2020 | 11.2 | -50.1% | SEC Filing ↗ |
| Q4 2019 | Dec 31, 2019 | 24.4 | -41.3% | SEC Filing ↗ |
| Q3 2019 | Sep 30, 2019 | 29.2 | – | SEC Filing ↗ |
| Q2 2019 | Jun 30, 2019 | 40.1 | – | SEC Filing ↗ |
| Q1 2019 | Mar 31, 2019 | 22.5 | – | SEC Filing ↗ |
| Q4 2018 | Dec 31, 2018 | 41.6 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Alpine Immune Sciences — Marketable securities ($M), quarterly Q4 2018–Q1 2024 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/alpine-mkt-sec
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.